Table 2.
Characteristic of the treatment with LCIG and levodopa-equivalent doses in the five patients.
| Patient | Age at the time of LCIG (years)∗ | LED pre-LCIG (mg)∗∗ | LED post-LCIG (LCIG + CR) 1st month (mg)∗∗∗ | LED post-LCIG (LCIG + CR) 12 months (mg)∗∗∗∗ | DBS ON/OFF at 12 months | Daily time spent in OFF after LCIG (UPDRS Item 39) | Functional impact of dyskinesias after LCIG (UPDRS item 33) |
|---|---|---|---|---|---|---|---|
| P1 | 71 | 2250 | 2164 | 2310 | OFF | 1 | 1 |
| P2 | 70 | 2400 | 2130 | 1960 | OFF | 1 | 1 |
| P3 | 59 | 855 | 1233 | 1098 | ON | 1 | 1 |
| P4 | 70 | 885 | 1638 | 1914 | ON | 1 | 1 |
| P5 | 66 | 1874 | 2100 | NA | ON | NA | NA |
∗Median age (years) at the time of LCIG: 66 IQR (59–71). ∗∗Median LED (mg) pre-LCIG: 1874 IQR (855–2400). ∗∗∗Median LED (mg) post-LCIG after 1 month: 2100 IQR (1233–2164). ∗∗∗∗Median LED (mg) post-LCIG after 12 months: 1937 IQR (1098–2310). LED pre-LCIG = total equivalent dose of levodopa oral medication; LED post-LCIG = total equivalent dose of levodopa after LCIG (LCIG plus oral control release); NA = not applicable; IQR = interquartile range.